Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFCD 1605-OPTIPRIME
2024-518740-20-00Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal adenocarcinoma (mCRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Disease control duration. Started Nov 2024; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-518740-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518740-20-00.